Elutia (ELUT)
Develops drug-eluting biomatrices for surgical reconstruction and implanted-device complications.
Something off on this page? Send us feedback.
Develops drug-eluting biological matrices and sells the SimpliDerm franchise for surgical reconstruction. After selling legacy Orthobiologics and CIED businesses, it is focused on the NXT-41 and NXT-41x pipeline, whose advancement depends on FDA authorization.
Develops drug-eluting biologics, combining local drug delivery with biological materials for surgical applications. The remaining commercial franchise is SimpliDerm, while NXT-41 and NXT-41x are being advanced for complications associated with implanted devices.
After rebranding from Aziyo Biologics and selling the Orthobiologics and CIED businesses, operations narrowed around this platform. The Gaithersburg, Maryland site supports development and is intended for commercial production if FDA authorizations are obtained.
Production, laboratory, and administrative activities are concentrated at the Gaithersburg site. Advancement of NXT-41 and NXT-41x and future commercial production depend on FDA authorization.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
No analyst notes in the last 24 months.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $19.9M · Total debt $10.8M · Total assets $43.6M · Shareholders' equity $15.7M
- Revenue
- $2.4M
- Operating income
- −$8.0M
- Net income
- −$7.6M
No dividends on record.
| Insiders | 21.62% | 9.58M shares | |
|---|---|---|---|
| 8 holders · as of Sep 14, 2026 | |||
| Strategic holders | 21.50% | 9.52M shares | |
| 1 holder · as of Mar 13, 2025 | |||
| Other | 56.88% | 25.19M shares | |
| remainder | |||
44.29M company shares as of Sep 22, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
HighCape Capital, L.P.Strategicdirector, 10 percent owner | 21.50% | 9.52M | filed Mar 13, 2025 |
Kevin Rakin1Insiderdirector, 10 percent owner | 11.84% | 5.24M | filed Jun 2, 2026 |
Nantahala Capital Management, LLCInstitution | 9.31% | 4.12M | filed Feb 13, 2026 |
Orin HirschmanInsider | 6.93% | 3.07M | filed Jan 28, 2026 |
Knollwood Investment Advisory, LLCInstitution | 5.77% | 2.56M | filed Feb 13, 2026 |
- Kevin Rakin's transaction reports restate only vehicles that traded; the 2025 ownership statement (5.24M) is used instead.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jan 30, 2026 | Guido J. Neels | director | +20,000 | $1.04 |
| Jan 30, 2026 | Kevin Rakin | director, 10 percent owner: | +70,000 | $1.06 |
| Jan 28, 2026 | Guido J. Neels | director | +15,000 | $1.06 |
| Jan 29, 2026 | Guido J. Neels | director | +15,000 | $1.06 |
| Dec 17, 2025 | Kevin Rakin | director, 10 percent owner: | +50,000 | $0.5199 |
- AbbVie
Human and animal-derived dermal matrices for surgical reconstruction
- Stryker
Human acellular dermal matrix for soft-tissue reconstruction
- Integra LifeSciences
Animal-derived biological mesh for soft-tissue reinforcement
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Elutia | $0.8102 | 0.00% | $37.7M | 0.9 | — | 3.1 | −61.3% |
| AbbVie | $265.01 | −0.10% | $467.37B | 74.5 | 17.5 | 7.3 | +10.2% |
| Stryker | $275.27 | +0.08% | $105.11B | 28.4 | 17.2 | 4.1 | +9.4% |
| Integra LifeSciences | $16.02 | +0.06% | $1.21B | — | 6.3 | 0.7 | +0.8% |
| Median | 51.5 | 17.2 | 4.1 | +9.4% |